新药时代双表达弥漫大B细胞淋巴瘤的治疗探索
Therapeutic exploration of double-expressor diffuse large B-cell lymphoma in the era of new drugs
王婕 1牛挺1
作者信息
- 1. 四川大学华西医院血液内科(成都,610041)
- 折叠
摘要
双表达MYC和BCL2是弥漫大B细胞淋巴瘤独立的预后因素,双表达淋巴瘤对标准的一线治疗方案R-CHOP反应不佳,5年总体生存率和无进展生存率显著缩短.如何提高和改善双表达淋巴瘤患者生存是临床上弥漫大B细胞淋巴瘤治疗的难点之一,迫切需要开发新型靶向药物和创新性疗法.在新药时代,针对双表达淋巴瘤的治疗探索正不断深入.本文根据新药的种类,介绍了针对双表达淋巴瘤开展的新药研究和治疗探索.
Abstract
Double-expressor of MYC and BCL2 is an independent prognostic factor for diffuse large B-cell lymphoma,and double-expressor lymphoma responds poorly to the standard first-line treatment regimen R-CHOP,with a significant shortening of 5-year overall survival and progression free survival.How to improve the survival of patients with double-expressor lymphoma is one of the difficulties in the treatment of diffuse large B-cell lymphoma in clinical practice,and there is an urgent need for the development of novel targeting agents and innovative therapies.In the era of new drugs,the therapeutic exploration of double-expressor lymphoma has been deepening,and this article introduces new drug clinical trials and therapeutic explorations carried out for double-expressor lymphoma based on the types of new drugs.
关键词
双表达/弥漫大B细胞淋巴瘤/新药治疗/临床试验Key words
double-expressor/diffuse large B-cell lymphoma/new drug therapy/clinical trial引用本文复制引用
出版年
2024
NETL
NSTL
万方数据